Compare RLX Technology Inc (RLX) vs Viatris Inc (VTRS) Price & Performance

RLX trades at $1.73, unchanged on the day, and has recently set new 52-week lows. The technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported $3.62B in 2025 revenue and $921.87M net income, though recent quarters show earnings misses against expectations. International expansion, now 70% of revenue, drives growth, but margin compression is a concern. Analyst coverage is limited, with a single hold rating indicating caution.

The outlook is mixed; strong international growth and a discounted valuation (P/E 15.46, P/B 0.91) offer potential upside, but persistent earnings misses, bearish technicals, and regulatory risks in the e-vapor industry pose significant headwinds. Investor sentiment remains neutral to cautious amid recent price weakness.

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.

The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.